308 results on '"Blagosklonny, Mv"'
Search Results
2. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy
3. Unwinding the loop of Bcl-2 phosphorylation
4. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells
5. Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells
6. Cell death beyond apoptosis
7. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition
8. Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal
9. Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells
10. STI-571 must select for drug-resistant cells but ‘no cell breathes fire out of its nostrils like a dragon’
11. The dilemma of apoptosis in myelodysplasia and leukemia: a new promise of therapeutic intervention?
12. Spotlight on apoptosis
13. Oligonucleotides protect cells from the cytotoxicity of several anti-cancer chemotherapeutic drugs
14. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs
15. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
16. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015
17. Targeted cancer therapy: the initial high concentration may slow down the selection for resistance.
18. From osimertinib to preemptive combinations.
19. My battle with cancer. Part 1.
20. Evaluation of off-label rapamycin use to promote healthspan in 333 adults.
21. Towards disease-oriented dosing of rapamycin for longevity: does aging exist or only age-related diseases?
22. Apoptotic cell death in disease-Current understanding of the NCCD 2023.
23. Cancer prevention with rapamycin.
24. Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells.
25. Cellular senescence: when growth stimulation meets cell cycle arrest.
26. Are menopause, aging and prostate cancer diseases?
27. Rapamycin treatment early in life reprograms aging: hyperfunction theory and clinical practice.
28. As expected, based on rapamycin-like p53-mediated gerosuppression, mTOR inhibition acts as a checkpoint in p53-mediated tumor suppression.
29. Cell senescence, rapamycin and hyperfunction theory of aging.
30. Hallmarks of cancer and hallmarks of aging.
31. Atlos Labs and the quest for immortality: but can we live longer right now?
32. As predicted by hyperfunction theory, rapamycin treatment during development extends lifespan.
33. No limit to maximal lifespan in humans: how to beat a 122-year-old record.
34. The hyperfunction theory of aging: three common misconceptions.
35. Anti-aging: senolytics or gerostatics (unconventional view).
36. Response to the Thought-Provoking Critique of Hyperfunction Theory by Aubrey de Grey.
37. DNA- and telomere-damage does not limit lifespan: evidence from rapamycin.
38. The goal of geroscience is life extension.
39. From causes of aging to death from COVID-19.
40. Rapamycin for the aging skin.
41. Rapamycin for longevity: opinion article.
42. The mystery of the ketogenic diet: benevolent pseudo-diabetes.
43. Fasting and rapamycin: diabetes versus benevolent glucose intolerance.
44. Paradoxes of senolytics.
45. Disease or not, aging is easily treatable.
46. Does rapamycin slow down time?
47. Addendum: Librarians against scientists: Oncotarget's lesson.
48. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.
49. Librarians against scientists: Oncotarget's lesson.
50. Rapamycin, proliferation and geroconversion to senescence.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.